Trial Search Results

A Ph 2 Study of Fosbretabulin in Subjects w Pancreatic or Gastrointestinal Neuroendocrine Tumors w Elevated Biomarkers

Intestinal neuroendocrine tumors develop in various locations in the body and have been associated with symptoms that are related to the flow of hormones or other substances into the blood stream. This is a research study of intestinal neuroendocrine tumors (NET) that are no longer responding to standard therapies. This research study is being done to see if fosbretabulin, a drug that blocks the blood vessels that feed the cancer, will reduce symptoms of NET and any biomarkers the tumor produces. This study will also include measuring quality of life while taking part in this study.

Stanford is currently not accepting patients for this trial.

Stanford Investigator(s):

Not currently accepting new patients for this trial

Contact Information

Stanford University
School of Medicine
300 Pasteur Drive
Stanford, CA 94305
CCTO
650-498-7061
Not Recruiting